Corona Remedies
Other · 3 quarters tracked · source-linked performance and management context.
Latest revenue
₹353 Cr
verified financial record
Quarters tracked
3
source records in the directory
Delivery assessment
Assessment incomplete
Across 4 tracked commitments. Delivery assessment incomplete while 1 remain unresolved or evidence-limited.
Call date
2026-04-30
latest available source date
Signal trajectory
1 actual quarterCurrent read
Assessment incomplete
Across 4 tracked commitments. Delivery assessment incomplete while 1 remain unresolved or evidence-limited.
Latest source read
What changed this quarter?
Corona Remedies delivered a strong FY26, with revenue of ₹1,403 Cr (+17.3% YoY) and PAT of ₹199 Cr (+33.4% YoY), exceeding guided ranges. EBITDA margin expanded 80bps to 20.9%, driven by favorable product mix and operating leverage. Domestic business grew 16.8%, while international surged 29.5%. Chronic segment now contributes 72% of revenue. Two brands crossed ₹100 Cr, and eight are in the ₹50-100 Cr club. Management guided for 15% organic revenue growth and 20%+ PAT growth in FY27, supported by new divisions (infertility, multispecialty), biosimilar launches (semaglutide), and acquisitions (Wokadin, Bayer portfolio). Key risk: potential gross margin pressure from rising API costs if geopolitical tensions persist.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹353 Cr
Source date
2026-04-30
Across the record
Quarter history.
History modules